Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cilostazol controlled release - Genovate Biotechnology

Next Previous
Drug Profile

Cilostazol controlled release - Genovate Biotechnology

Alternative Names: Pletaal®; PMR

Latest Information Update: 28 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genovate Biotechnology
  • Class Antiplatelets; Quinolines; Small molecules; Tetrazoles
  • Mechanism of Action Platelet aggregation inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Intermittent claudication

Most Recent Events

  • 28 Aug 2025 No recent reports of development identified for phase-I development in Intermittent-claudication(In volunteers) in USA (PO, Tablet)
  • 28 May 2024 Genovate Biotechnology intends to submit a New Drug Application (NDA) for cilostazol (PMR) for intermittent claudication [PO,Controlled release] in the US, in the second half of 2025
  • 18 Jan 2024 Genovate Biotechnology completes a phase I trial in Intermittent claudication (In volunteers) in USA (PO) (NCT06167265)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top